BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 29559584)

  • 1. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
    Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
    Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
    Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
    Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
    Yi JS; Perla S; Enyenihi L; Bennett AM
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
    Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.
    Paardekooper Overman J; Yi JS; Bonetti M; Soulsby M; Preisinger C; Stokes MP; Hui L; Silva JC; Overvoorde J; Giansanti P; Heck AJ; Kontaridis MI; den Hertog J; Bennett AM
    Mol Cell Biol; 2014 Aug; 34(15):2874-89. PubMed ID: 24865967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
    Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
    PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
    Jopling C; van Geemen D; den Hertog J
    PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).
    Qiu W; Wang X; Romanov V; Hutchinson A; Lin A; Ruzanov M; Battaile KP; Pai EF; Neel BG; Chirgadze NY
    BMC Struct Biol; 2014 Mar; 14():10. PubMed ID: 24628801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype.
    Edwards JJ; Martinelli S; Pannone L; Lo IF; Shi L; Edelmann L; Tartaglia M; Luk HM; Gelb BD
    Am J Med Genet A; 2014 Sep; 164A(9):2351-5. PubMed ID: 24891296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.
    Kontaridis MI; Swanson KD; David FS; Barford D; Neel BG
    J Biol Chem; 2006 Mar; 281(10):6785-92. PubMed ID: 16377799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compound heterozygosity for PTPN11 variants in a subject with Noonan syndrome provides insights into the mechanism of SHP2-related disorders.
    Lorca R; Pannone L; Cuesta-Llavona E; Bocchinfuso G; Rodríguez-Reguero J; Carpentieri G; Hernando I; Flex E; Tartaglia M; Coto E; Gómez J; Martinelli S
    Clin Genet; 2021 Mar; 99(3):457-461. PubMed ID: 33354767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.
    Stewart RA; Sanda T; Widlund HR; Zhu S; Swanson KD; Hurley AD; Bentires-Alj M; Fisher DE; Kontaridis MI; Look AT; Neel BG
    Dev Cell; 2010 May; 18(5):750-62. PubMed ID: 20493809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
    Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
    Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SHP2 sails from physiology to pathology.
    Tajan M; de Rocca Serra A; Valet P; Edouard T; Yart A
    Eur J Med Genet; 2015 Oct; 58(10):509-25. PubMed ID: 26341048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
    Lauriol J; Cabrera JR; Roy A; Keith K; Hough SM; Damilano F; Wang B; Segarra GC; Flessa ME; Miller LE; Das S; Bronson R; Lee KH; Kontaridis MI
    J Clin Invest; 2016 Aug; 126(8):2989-3005. PubMed ID: 27348588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds.
    Guo W; Xu Q
    J Pharmacol Sci; 2020 Nov; 144(3):139-146. PubMed ID: 32921395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase.
    Miura K; Wakayama Y; Tanino M; Orba Y; Sawa H; Hatakeyama M; Tanaka S; Sabe H; Mochizuki N
    Oncogene; 2013 Nov; 32(45):5292-301. PubMed ID: 23318428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.
    Yu ZH; Xu J; Walls CD; Chen L; Zhang S; Zhang R; Wu L; Wang L; Liu S; Zhang ZY
    J Biol Chem; 2013 Apr; 288(15):10472-82. PubMed ID: 23457302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
    Martinelli S; Torreri P; Tinti M; Stella L; Bocchinfuso G; Flex E; Grottesi A; Ceccarini M; Palleschi A; Cesareni G; Castagnoli L; Petrucci TC; Gelb BD; Tartaglia M
    Hum Mol Genet; 2008 Jul; 17(13):2018-29. PubMed ID: 18372317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.
    Yu ZH; Zhang RY; Walls CD; Chen L; Zhang S; Wu L; Liu S; Zhang ZY
    Biochemistry; 2014 Jul; 53(25):4136-51. PubMed ID: 24935154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.